08Jan 2023
Lecanemab trial in AD brings hope but requires greater clarity

Lecanemab trial in AD brings hope but requires greater clarity

The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical benefit in people with Alzheimer's disease. However, several questions remain regarding the true clinical relevance, safety, and accessibility of lecanemab in this patient population.

  • #neurology

Like

Save

Share